A study to identify factors that are associated with improved effectiveness in pharmacologic therapy of Overactive Bladder, from the patient perspective primarily measured by OAB-Q-SF (Overactive Bladder Questionnaire Short Form)
Study Type
OBSERVATIONAL
Enrollment
1,524
oral
oral
Change from baseline in OAB-related QoL and symptom bother
Overactive Bladder (OAB), Quality of Life (QoL). As measured by the Overactive Bladder Questionnaire Short Form (OAB-Q-SF) questionnaire scores
Time frame: Baseline, Month 1, 3, 6 and 12
Effectiveness as measured by impression of severity of OAB
Via the Patient Perception of Bladder Condition \[PPBC\]
Time frame: Baseline, Month 1, 3, 6 and 12
Effectiveness as measured by general health related QoL
via the EuroQol 5D \[EQ-5D\]
Time frame: Baseline, Month 1, 3, 6 and 12
Persistence with OAB drug treatment
The duration of time a patient continues to take the prescribed medication
Time frame: Baseline till End of Study (ESV) (up to month 12)
Use of additional (add-on) medications
As reported by patients and HCP
Time frame: Baseline till ESV (up to month 12)
Switching of medication
As reported by patients and HCP
Time frame: Baseline till ESV (up to month 12)
OAB drug treatment satisfaction
Via the Overactive Bladder Treatment Satisfaction Questionnaire (OAB-S)
Time frame: Baseline, month 1, 3, 6 and 12
Reasons for switching of medication
As reported by patients and HCP for each specific medication, number and percent
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Site US1051
Birmingham, Alabama, United States
Site US1094
Birmingham, Alabama, United States
Site US1010
Huntsville, Alabama, United States
Site US1020
Mobile, Alabama, United States
Site US1006
Goodyear, Arizona, United States
Site US1036
Mesa, Arizona, United States
Site US1028
Phoenix, Arizona, United States
Site US1100
Tucson, Arizona, United States
Site US1083
Tucson, Arizona, United States
Site US1114
Little Rock, Arkansas, United States
...and 82 more locations
Time frame: Baseline till ESV (up to month 12)
Reasons for discontinuation of medication
As reported by patients and HCP for each specific medication, number and percent
Time frame: Baseline till ESV (up to month 12)
Reasons for add-on medication
As reported by patients and HCP for each specific medication, number and percent
Time frame: Baseline till ESV (up to month 12)
Reasons for dose titration
As reported by patients and HCP for each specific medication
Time frame: Baseline till ESV (up to month 12)
Frequency of dose titration
As reported by patients and HCP for each specific medication
Time frame: Baseline till ESV (up to month 12)
Safety profile as assessed by recording AEs and SAEs
Adverse Events (AEs), Serious Adverse Events (SAEs)
Time frame: Baseline till ESV (up to month 12)